

.....

Contents

Session I

Regulatory Requirements	1
Chairs: <i>J.H. Trouvin (AFSSAPS)</i> <i>A. Farrugia (TGA)</i>	
European Regulatory Guidance on Virus Safety of Recombinant Proteins, Monoclonal Antibodies and Plasma Derived Medicinal Products	3
<i>P. Celis, G. Silvester</i>	
Viral Safety Evaluation of Plasma-Derived Therapeutic Products	11
<i>M. Farshid</i>	
Current and Future Approaches to Ensure the Viral Safety of Biopharmaceuticals	17
<i>K. Brorson, L. Norling, E. Hamilton, S. Lute, K. Lee, S. Curtis, Y. Xu</i>	
An Industry Perspective on Plasma-Derived Products	31
<i>I. von Hoegen</i>	
Industry Perspective for Biotech Products	37
<i>A. Möritz</i>	

Session II

Testing Source Material	45
Chairs: <i>P. Korhola (NAM)</i> <i>G. Vicari</i>	
Developing New Infectivity Assays	47
<i>D.N. Galbraith</i>	
Qualification of Virus/Cell Systems for their Intended Use	55
<i>A. Gröner</i>	
West Nile Virus NAT Testing	65
<i>J. Saldanha, C. Cameron</i>	
Variants of B19	71
<i>K.E. Brown</i>	

Session III (1)

Virus Validation, Virus Assay and Standardisation	79
Chairs: <i>H. Willkommen (Clearant)</i> <i>G. Rössling (Schering)</i>	
Quantitative NAT for Pathogen Inactivation Verification	81
<i>K. McKenney, L. Gillmeister, K. Marlowe, D. Armistead, W. Burgess, W. Drohan</i>	
Use of Bacteriophages as Surrogates for Mammalian Viruses	89
<i>M. McAlister, H. Aranha, R. Larson</i>	

Session III (2)

Virus Validation, Model Viruses	99
Chairs: <i>H. Willkommen</i> (Clearant) <i>G. Rössling</i> (Schering)	

West Nile Virus: Recent Experience with the Model Virus Approach	101
<i>T.R. Kreil</i>	
Cell Culture-Based Assay of Parvovirus B19 and the Relevance of Animal Model Viruses	107
<i>J. Blümel</i>	
Methods for Validation of Hepatitis B Virus Inactivation	113
<i>W.H. Gerlich, D. Glebe</i>	

Session IV

Virus Inactivation/Removal Technologies: Application and Validation	123
Chairs: <i>J. Löwer</i> (PEI) <i>E.-G. Graf</i> (Pall)	

Robustness Studies on Virus Inactivation: Definition of Parameters and their Generic Use	125
<i>H. Dichtelmüller</i>	
PDA Virus Filter Task Force Update	129
<i>G. Sofer</i>	
Gamma Irradiation of Intravenous Immunoglobulin	133
<i>W.N. Drohan, S.I. Miekka, Y.V. Griko, R.-Y. Forng, R.E. Stafford, C.R. Hill, D.M. Mann,</i> <i>W.H. Burgess</i>	
UV-C Irradiation of Human Albumin Solution on Manufacturing Scale	139
<i>A.J. MacLeod</i>	

Session V

Virus Safety Aspects of Advanced Technology Medicinal Products	149
Chairs: <i>J. Robertson</i> (NIBSC) <i>H. Willkommen</i> (Clearant)	

Virological Issues in the Use of Cell Therapies	151
<i>P.D. Minor</i>	
Animal Virus Contaminants of Biotechnology Products	155
<i>D. Onions</i>	
Transgenic Animals for the Production of Biological Medicines	165
<i>P.D. Minor</i>	